Biotech ETFs Stable Despite Disappointing Treatment Date From Gilead

Investors who were attaching their hopes for a swift end to the coronavirus pandemic to the antiviral medicine remdesivir from Gilead Sciences were disappointed, as Gilead released news Thursday that while the data suggests a “potential benefit,” the drug failed to increase the improvement of...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.